Samso News: Control Bionics Limited — U.S. Pilot Distribution Agreement with Tobii Dynavox
- Noel Ong
- 3 hours ago
- 5 min read
Announcement
Tobii Dynavox - Distribution Partnership - 27 January 2026 (view the announcement)
AGM Presentation 25 November 2025 (view the announcement)
Control Bionics looks like it is at the intersection of regulated med-tech, assistive communication, and scalable distribution models. This update focuses on partner-led market access in the United States, leveraging existing reimbursement frameworks rather than direct-to-consumer expansion. Could this be a very interesting time for the company?
Introducing Control Bionics Limited – Expanding NeuroNode Access in the U.S. AAC Market
Control Bionics Limited (ASX: CBL) has announced a new agreement with Tobii Dynavox, a global leader in Augmentative and Alternative Communication (AAC), to evaluate a potential U.S. distribution partnership for its NeuroNode® technology. The agreement initiates a six-month pilot program across five north-western U.S. states, positioning NeuroNode alongside Tobii Dynavox’s established communication aids.
Highlights – U.S. Distribution Pilot with a Global AAC Leader
Control Bionics has entered into a six-month pilot agreement with Tobii Dynavox to evaluate distribution of NeuroNode® in the United States, replacing a previous U.S. partner within Tobii Dynavox’s ecosystem.
The pilot will run across five states in the north-western U.S., providing real-world feedback on integration, user adoption, and distributor workflows within an established AAC sales.
NeuroNode is positioned as a complementary access method to Tobii Dynavox’s existing AAC solutions, offering eye-gaze users an additional input modality where traditional access methods may be limited.
Control Bionics’ NeuroNode technology (Figure 1) is based on surface electromyography (sEMG), enabling control through minimal muscle activation and supporting users with severe physical impairment.
Figure 1: NeuroNode® Product (source: CBL)
The pilot aligns with Control Bionics’ broader strategy to transition NeuroNode sales toward wholesale distribution (Figure 2), supported by a rare U.S. HCPCS reimbursement code that underpins scalable market access.
Figure 2: NeuroNode® wholesale (source: CBL)
Leadership Commentary
Control Bionics CEO, Jeremy Steele, commented:
“Tobii Dynavox is a global leader in AAC, and we are pleased to be partnering with them to introduce NeuroNode into selected regions of the U.S. market. We believe this collaboration has the potential to meaningfully enhance how people access and use communication technology. While this is an initial six-month pilot, we see real potential in the partnership, and we look forward to exploring the opportunity for a broader U.S. expansion over time.”
Near-term Milestones to Watch
Completion of the six-month U.S. pilot program with Tobii Dynavox.
Assessment of distributor performance and user adoption outcomes.
Potential expansion into a broader U.S. distribution agreement following pilot review.
Progress on additional wholesale partnerships aligned with NeuroNode’s reimbursement pathway.
Samso Concluding Comments
Control Bionics is taking a realistic approach to U.S. expansion by aligning with an established AAC distributor rather than building new infrastructure. This does reflect a focus on efficiency and a pathway to be critically focused on capital discipline.
The NeuroNode technology fits within an existing reimbursement and clinical workflow framework. That alignment lowers barriers to adoption and supports repeatable sales models.
It is very important to remember that the pilot agreement does not guarantee a long-term partnership, but it provides a structured pathway to assess commercial fit. Outcomes from this process will be more informative than early announcements.
Samso will continue to follow how Control Bionics converts technical capability into scalable distribution. The results of this pilot will be a key data point for future assessment.
Market Implication - The Investor Lens
CBL has a market capitalisation of just over AUD $24M and by the look of Figure 3, the share price chart does not look overly inspiring. Samso has not been following the story hard and it does show that maybe, we need to dig more into this business with more importance.
Figure 3: The CBL share price chart as of 9th February 2026. (source: commsec)
I do like the business but I will be the first one to say that a lot more research is required.
The Samso Way – Seek the Research
Here at Samso, we pride ourselves on delivering content for investors that is independent and informed by over three decades of experience in the industry. Our content is well-researched and is only created if I see merit in discussing the company's story.
Our mission is simple: cut through the noise and spotlight what matters—genuine stories, grounded insights, and real opportunity.
Our content is well-researched and is only created if the team sees merit in discussing the company or concept. Investors can explore our three core platforms:
There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals.
Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn’t built in a day, and the Great Wall stood because it took centuries to complete.
The Samso Philosophy:
Stay curious. Stay sharp. And remember—digging deeper always uncovers the real value.
In Life, there is no such thing as a Free Lunch.
Never bite off more than you can chew is my parting comment.
Happy Investing, and the only four-letter word you need to know is DYOR.
To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiate for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.
Disclaimer
The information or opinions provided herein do not constitute investment advice, an offer, or solicitation to subscribe for, purchase, or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints.
Share to Grow: Your Bonus
Samso has just released an eBook: How to Add Value to your Share Portfolio
A lesson on geological models sought by mining companies that gives insight and an understanding of which portfolios are better - and potentially more lucrative – investments. Click here to download this eBook.
If you find this article informative and useful, please help me share the information. I try to write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation sees the benefit of what Samso is trying to achieve and has a need to share your journey, please contact me at noel.ong@samso.com.au.
Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insights from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.
Comments